How Australian Scientists Discovered a New Immune Pathway in Rheumatic Heart Disease?
🌏 Available in: English | 한국어
An Australian Discovery Reveals a Dysregulated Immune Pathway in Acute Rheumatic Fever
How a Common Infection Can Lead to Lifelong Heart Disease
Every year, hundreds of millions of people are infected with Group A Streptococcus (GAS). For almost everyone, it is a routine infection that disappears within days. But for a small number of people, the real disease begins only after the bacteria are gone. Years later, their immune system continues attacking the heart, eventually causing permanent valve damage known as rheumatic heart disease.
Why does this happen? In 2018, Australian researchers reported a discovery in Circulation that provided a new piece of the puzzle, revealing an immune pathway that may help explain why inflammation persists long after the initial infection has resolved.
Molecular Mimicry: When Immune Cells That Fight Bacteria Turn Against the Heart
For decades, scientists believed that molecular mimicry was the primary mechanism underlying acute rheumatic fever.
Certain proteins produced by Group A Streptococcus (GAS) closely resemble proteins found in human heart valves, cardiac muscle, and joints. As a result, antibodies and T cells generated to eliminate the bacteria may mistakenly recognize and attack the body's own tissues.
This misguided immune response triggers the release of inflammatory cytokines, and repeated episodes of inflammation gradually damage the heart valves, eventually leading to rheumatic heart disease.
However, molecular mimicry alone could not explain why the disease persists in only a small proportion of patients after the bacterial infection has already been cleared.
Discovery of the IL-1β–GM-CSF–CD4 T Cell Axis
Australian researchers investigated this question by studying peripheral blood mononuclear cells (PBMCs) from patients with acute rheumatic fever.
By stimulating patient immune cells with GAS-related signals, researchers identified a unique inflammatory pattern that distinguished ARF patients from healthy individuals.
The major discoveries included three key findings.
1. Persistent IL-1β Production Drives Inflammation
The study found increased production of IL-1β, a powerful inflammatory cytokine, in immune cells from ARF patients.
IL-1β normally plays an essential role in early immune defense against infections. However, excessive or prolonged IL-1β activity can promote chronic inflammation and tissue damage.
In ARF, persistent IL-1β signaling appeared to act as an upstream trigger that maintained inflammatory immune activation.
2. Expansion of GM-CSF-Producing CD4 T Cells
A major discovery was that IL-1β promoted the expansion of a specific population of inflammatory CD4 T cells.
These cells produced:
GM-CSF (granulocyte-macrophage colony-stimulating factor)
GM-CSF is an important immune regulator that activates macrophages and inflammatory cells.
While useful during infection, excessive GM-CSF production can create a damaging inflammatory environment.
The study showed that ARF patients displayed increased GM-CSF-producing CD4 T cell responses, suggesting a mechanism linking infection-triggered inflammation with autoimmune tissue injury.
3. The Role of CXCR3⁺ CCR4⁻ CCR6⁻ CD4 T Cells
The research identified a specific memory T cell population:
CXCR3⁺ CCR4⁻ CCR6⁻ CD4 T cells
as an important source of GM-CSF production.
These cells are associated with inflammatory immune responses and may migrate toward inflamed tissues, potentially contributing to cardiac valve injury.
The proposed disease model became:
Group A Streptococcus infection
↓
Excessive IL-1β activation
↓
Expansion of GM-CSF-producing CD4 T cells
↓
Persistent inflammatory response
↓
Heart valve damage
Rather than viewing acute rheumatic fever solely as a consequence of bacterial infection, this study suggests that dysregulated immune signaling may play a central role in driving disease progression long after the bacteria have been eliminated.
Repurposing an Old Drug: Hydroxychloroquine as a Potential Therapy
One of the most interesting aspects of this research was the exploration of an existing drug for a new purpose.
Hydroxychloroquine (HCQ) has been widely used for decades to treat autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus.
Researchers investigated whether HCQ could suppress the abnormal immune activation observed in ARF.
The study demonstrated that HCQ could:
Reduce IL-1β-driven GM-CSF expression
Suppress expansion of inflammatory CD4 T cells
Modulate abnormal immune activation patterns
These findings suggested that HCQ could potentially be repurposed as an immune-modulating therapy for ARF and RHD.
Currently, the main strategy for preventing RHD remains long-term antibiotic prophylaxis to prevent recurrent GAS infection.
However, therapies directly targeting the abnormal immune response remain limited.
Therefore, drug repurposing approaches such as HCQ provide a promising direction for future treatment development.
Related Articles
Landmark Publication
Kim ML et al.
"Dysregulated IL-1β-GM-CSF Axis in Acute Rheumatic Fever That Is Limited by Hydroxychloroquine"
Circulation. 2018;138(23):2648-2661.
This study provided several important discoveries:
Identification of the IL-1β–GM-CSF inflammatory pathway in ARF
Discovery of GM-CSF-producing inflammatory CD4 T cells
Demonstration that hydroxychloroquine could modulate this immune pathway
This work provided new insight into how abnormal immune regulation contributes to rheumatic heart disease.
From an Indigenous Health Challenge to Global Immunology Discovery
The study of rheumatic heart disease is not only about solving a regional health problem.
It addresses a much broader biological question:
Why does the human immune system sometimes fail to stop after eliminating an infection and begin attacking the body itself?
Research into ARF and RHD in Australia has helped reveal important connections between infection, inflammation, and autoimmune disease.
The IL-1β–GM-CSF–CD4 T cell pathway represents a new framework for understanding post-infectious immune disorders and may guide future development of precision immunotherapies.
Great scientific discoveries do not always begin in large laboratories or with obvious breakthroughs.
Sometimes they begin with a simple question from a community facing a serious health challenge.
And the answer can eventually change the future of medicine.
Frequently Asked Questions (FAQ)
What causes rheumatic heart disease?
Rheumatic heart disease is caused by an abnormal immune response following infection with Group A Streptococcus (GAS), a common bacterium responsible for throat and skin infections.
In some individuals, the immune system mistakenly attacks the body's own tissues after fighting the infection. This inflammatory process can damage heart valves, leading to chronic valve disease and heart failure.
The condition usually develops after repeated episodes of acute rheumatic fever (ARF).
Why is rheumatic heart disease more common in Indigenous Australians?
Rheumatic heart disease remains a significant health issue among Aboriginal and Torres Strait Islander communities because of a combination of social, environmental, and healthcare factors.
Higher rates of GAS infections, challenges in healthcare access, overcrowded living conditions, and barriers to early diagnosis and treatment contribute to the continuing burden of ARF and RHD.
Australian researchers have worked closely with Indigenous communities to improve prevention strategies, early detection, and long-term management of the disease.
Can rheumatic heart disease be cured?
Rheumatic heart disease can be prevented and managed, but advanced heart valve damage is often permanent.
The most effective prevention strategy is avoiding recurrent GAS infections through long-term antibiotic prophylaxis, usually with regular penicillin injections.
Once significant valve damage occurs, some patients may require surgical valve repair or replacement.
Current research is exploring new approaches that target the abnormal immune response itself, including immune-modulating therapies.
What is the IL-1β–GM-CSF–CD4 T cell pathway?
The IL-1β–GM-CSF–CD4 T cell pathway describes a chain of immune events involved in inflammatory activation:
GAS infection → IL-1β activation → GM-CSF-producing CD4 T cell expansion → persistent inflammation → heart valve damage
Understanding this pathway has helped researchers move beyond the idea that rheumatic heart disease is only an infection-related complication and recognize it as a complex immune-mediated disease.
What was the major discovery in the Australian rheumatic heart disease study?
A landmark Australian study published in Circulation in 2018 identified a dysregulated IL-1β–GM-CSF inflammatory pathway in acute rheumatic fever.
The study demonstrated:
Increased IL-1β inflammatory signaling
Expansion of GM-CSF-producing CD4 T cells
Potential immune regulation by hydroxychloroquine
This research provided a new framework for understanding the immune mechanisms behind rheumatic heart disease and opened possibilities for future targeted immunotherapies.